Optimizing Infectious Disease Denial Appeal Automation

For infectious disease (ID) practices, efficient denial appeal automation is critical to maintaining revenue streams and ensuring patient access to high-cost therapies.

Managing prior authorization (PA) denials for infectious disease treatments, particularly high-cost antivirals, antifungals, and Outpatient Parenteral Antimicrobial Therapy (OPAT), presents significant challenges. Without automation, the manual appeal process drains staff resources, delays patient care, and leads to lost revenue from unrecovered claims. Klivira's platform addresses these specific pain points for ID.

The Challenge of Denials in Infectious Disease

Infectious disease specialists frequently encounter PA denials due to the complexity and cost of treatments. These often involve high-cost antivirals (e.g., for HCV, HIV), antifungals, and OPAT regimens, which require extensive clinical documentation and adherence to specific payer criteria. Manual appeal processes are prone to errors, leading to delayed care and financial strain on clinics and health systems.

Common ID Treatments Triggering Prior Authorization Denials

Prior authorization is frequently required for critical infectious disease therapies, making them prime candidates for denial and subsequent appeal workflows. These include:

Key PA Categories in ID:

**Antivirals:** High-cost regimens for Hepatitis C (HCV) and Human Immunodeficiency Virus (HIV) often face stringent medical necessity reviews.
**Antifungals:** Advanced antifungal agents for systemic infections typically require detailed clinical justification.
**Outpatient Parenteral Antimicrobial Therapy (OPAT):** Long-term IV antibiotic treatments administered in an outpatient setting are frequently denied due to site-of-care or medical necessity criteria.

Transforming ID Denial Appeals with Automation

Traditional denial appeal workflows are resource-intensive. Staff must manually gather documentation, draft appeal letters, navigate varying payer appeal pathways, and track statuses. This leads to documentation gaps, timely-filing breaches, and inconsistent appeal quality, all of which are amplified in the urgent context of infectious disease care. Klivira's platform provides a robust solution to these challenges.

Klivira's Automated Appeal Workflow for Infectious Disease

Klivira's denial appeal automation streamlines the entire process, specifically addressing the needs of infectious disease practices. Our system integrates with your EMR and payer portals to ensure efficient, evidence-based appeal submissions, leveraging capabilities like normalized CARC/RARC taxonomy for denial classification and automated status tracking.

Key Automation Steps:

**Denial Classification & Pathway Selection:** Klivira's denial-router uses normalized CARC/RARC taxonomy to classify denials and select the appropriate appeal pathway based on payer-specific policies, critical for navigating complex ID treatment coverage.
**FHIR-based Documentation Re-discovery:** The platform pulls additional clinical documentation from the EMR, including new lab results, imaging, updated problem lists, and peer-reviewed literature relevant to off-label ID cases, ensuring comprehensive appeal packets.
**Appeal-Letter Template Assembly:** Klivira composes payer-specific appeal letters, drafting clinician-reviewable content for clinical-necessity appeals that cites relevant clinical evidence and guidelines, such as those often referenced for antimicrobial stewardship.
**Automated Submission & Tracking:** Appeals are submitted via the payer's accepted channel (portal, fax, or PAS-conformant resubmission), with automated status tracking, timely-filing window enforcement, and escalation rules to prevent lost-to-follow-up cases.
**Outcome Capture & Feedback:** Appeal outcomes are captured and written back to the EMR, triggering downstream billing workflows and providing pattern feedback to optimize future PA submissions for ID treatments.

Addressing ID-Specific Failure Modes

Klivira's automation directly mitigates common failure points in infectious disease denial appeals. We eliminate documentation gaps through automated FHIR-based re-discovery, prevent wrong appeal levels via payer-policy-aware pathway selection, and ensure timely submissions with automated window enforcement. This consistency and efficiency are vital for high-cost, time-sensitive ID therapies like OPAT, reducing rework costs as highlighted by the CAQH Index.

Frequently asked questions

How does Klivira handle appeals for OPAT denials?

Klivira's system classifies OPAT denials based on CARC/RARC codes and payer policies, then automatically gathers necessary clinical evidence, including detailed treatment plans and patient progress notes via FHIR, to support the medical necessity and site-of-care arguments in the appeal letter. Automated tracking ensures timely submission and follow-up, crucial for continuous patient care.

Can Klivira integrate with our existing EMR for infectious disease patient data?

Yes, Klivira is designed for seamless integration with major EMR systems using SMART on FHIR standards. This allows for automated extraction of relevant clinical documentation, such as lab results, physician notes, and medication lists, directly from the patient chart to build comprehensive appeal packets for infectious disease cases.

What types of denial reasons does Klivira's automation address for ID treatments?

Klivira addresses a wide range of denial reasons common in infectious disease, including medical necessity, lack of documentation, incorrect coding, and formulary restrictions. By leveraging normalized CARC/RARC taxonomy and a comprehensive payer-policy library, the system tailors the appeal strategy to the specific denial reason, enhancing success rates.

How does Klivira ensure appeal letters for ID cases are clinically robust?

For clinical-necessity appeals involving complex ID treatments, Klivira's system drafts initial appeal letters using payer-specific templates and automatically pulls relevant clinical evidence and literature citations. These letters are then presented to clinicians for review and approval, ensuring accuracy and clinical rigor before submission.

Does Klivira assist with appeals for off-label use of ID medications?

Yes, for off-label use cases common in infectious disease, Klivira's documentation re-discovery capabilities can identify and pull peer-reviewed literature and clinical trial data from the EMR or linked databases. This evidence is then integrated into the appeal letter, providing strong support for medical necessity based on established clinical evidence.